Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety was written by Richardson, Timothy I.;Frank, Scott A.;Wang, Minmin;Clarke, Christian A.;Jones, Scott A.;Ying, Bai-Ping;Kohlman, Dan T.;Wallace, Owen B.;Shepherd, Timothy A.;Dally, Robert D.;Palkowitz, Alan D.;Geiser, Andrew G.;Bryant, Henry U.;Henck, Judith W.;Cohen, Ilene R.;Rudmann, Daniel G.;McCann, Denis J.;Coutant, David E.;Oldham, Samuel W.;Hummel, Conrad W.;Fong, Kin C.;Hinklin, Ronald;Lewis, George;Tian, Hongqi;Dodge, Jeffrey A.. And the article was included in Bioorganic & Medicinal Chemistry Letters in 2007.Reference of 90560-10-4 This article mentions the following:
Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation. In the experiment, the researchers used many compounds, for example, 6-Methoxybenzo[b]thiophene (cas: 90560-10-4Reference of 90560-10-4).
6-Methoxybenzo[b]thiophene (cas: 90560-10-4) belongs to benzothiophene derivatives. Benzothiophene is used as starting material for the synthesis of bioactive molecules. The core structure is a part of various pharmaceutical substances and natural products. It is found within the chemical structures of pharmaceutical drugs such as raloxifene, zileuton, and sertaconazole, and also BTCP.Reference of 90560-10-4
Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem